Please login to order a test.
Acetylcholine Receptor (AChR)-blocking Antibodies
- AChR-blocking Antibodies
- Anti-AChR Antibody
- Myasthenia Gravis Antibody
This assay is a secondary test for confirming the diagnosis of acquired myasthenia gravis.1
AChR autoantibodies are not typically found in congenital myasthenia.
This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.
This assay measures antibodies that inhibit the binding of radiolabeled alpha-bungarotoxin (α-BTX) to solublized muscle AChR.
Myasthenia gravis is an acquired disorder of neuromuscular transmission characterized by use-associated muscle weakness and fatigability.1 This condition frequently involves the extraocular muscles and has a strong association with tumor of the thymus (thymoma). The disease has a prevalence of approximately 5 per 100,000 individuals and can occur at any age. In women, the disease usually presents between the ages of 20 and 40 years, while disease onset in men typically occurs later in life. AChR blocking antibodies are observed in 52% of patients with autoimmune myasthenia gravis.1 These autoantibodies interfere with normal neuromuscular function, causing muscle weakness and fatigue. Approximately 1% of individuals are positive for AChR blocking antibodies in the absence of AChR binding antibodies.1
0.3 mL (Note: This volume does not allow for repeat testing.)
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|085926||AChR Blocking Abs, Serum||11561-8||085927||AChR Blocking Abs, Serum||%||11561-8|